Valproic acid oral - Onxeo

Drug Profile

Valproic acid oral - Onxeo

Alternative Names: G2M-777; PEAC; Pulse Enhanced Acetylation; Savicol

Latest Information Update: 04 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TopoTarget
  • Developer Onxeo SA
  • Class Antiepileptic drugs; Antimigraines; Nootropics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Familial adenomatous polyposis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Sep 2014 Discontinued - Phase-II for Familial adenomatous polyposis in Germany (PO)
  • 04 Sep 2014 Discontinued - Phase-II for Familial adenomatous polyposis in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top